IBOV 172,457.76 ▲ 0.66% IPC MEX 71,610.23 ▼ 0.28% MERVAL 2,848,945 — — USD/BRL5.67▲ 0.45% USD/MXN18.52▼ 0.42% USD/CLP994.16▼ 0.13% USD/COP3,302▲ 0.70% USD/PEN3.40▼ 0.16% USD/ARS1,544▼ 0.11% USD/UYU40.59▲ 2.33% USD/PYG6,196▲ 2.33% USD/BOB11.59▼ 0.37% USD/DOP60.59▲ 1.85% USD/CRC442.74▼ 0.10% USD/GTQ7.64▲ 2.06% USD/HNL26.91▲ 2.15% USD/NIO36.62▲ 1.57% USD/VES909.35▼ 0.13% USD/PAB1.00— 0.00% USD/BZD2.00— 0.00% USD/JMD157.69▲ 1.39% USD/TTD6.75▲ 1.58% EUR/BRL6.25▲ 0.93% BRENT 96.08 ▲ 0.27% WTI 88.92 ▲ 0.20% IRON ORE 161.91 — — COPPER 6.06 ▼ 1.93% GOLD 3,888 ▲ 0.06% SILVER 48.65 ▼ 2.65% SOY 1,233 ▲ 0.47% CORN 446.00 ▲ 0.79% WHEAT 593.50 ▲ 1.58% COFFEE 274.00 ▼ 2.21% SUGAR 18.40 ▲ 0.99% ORANGE JUICE 136.85 ▼ 2.91% COTTON 79.02 ▲ 0.44% COCOA 5,267 ▲ 3.97% BEEF 224.93 ▲ 2.75% CATTLE 335.65 ▼ 0.01% LITHIUM 58.76 ▼ 3.78% PETR4 45.30 ▲ 1.34% VALE3 63.50 ▼ 0.70% ITUB4 42.27 ▲ 1.42% BBDC4 14.52 ▲ 1.40% ABEV3 15.79 ▲ 0.25% BBAS3 15.10 ▼ 2.45% B3SA3 14.89 ▲ 0.88% WEGE3 51.31 ▼ 0.66% PRIO3 63.30 — 0.00% SUZB3 54.77 ▼ 2.27% RENT3 30.07 ▲ 1.66% AZZA3 15.91 ▼ 5.86% CSAN3 3.10 ▲ 8.77% RAIZ4 20.00 ▼ 6.67% PCAR3 2.56 ▲ 7.11% GMAT3 4.25 ▲ 10.68% PSSA3 46.41 ▲ 1.02% CVCB3 0.83 ▼ 1.19% POSI3 3.15 ▼ 6.53% SLCE3 18.28 ▼ 0.44% NATU3 5.13 ▼ 3.75% BRKM5 3.02 ▼ 1.63% RANI3 8.18 — 0.00% CSNA3 3.72 ▼ 12.06% IBOV 172,457.76 ▲ 0.66% IPC MEX 71,610.23 ▼ 0.28% MERVAL 2,848,945 — — USD/BRL 5.67 ▲ 0.45% USD/MXN 18.52 ▼ 0.42% USD/CLP 994.16 ▼ 0.13% USD/COP 3,302 ▲ 0.70% USD/PEN 3.40 ▼ 0.16% USD/ARS 1,544 ▼ 0.11% USD/UYU 40.59 ▲ 2.33% USD/PYG 6,196 ▲ 2.33% USD/BOB 11.59 ▼ 0.37% USD/DOP 60.59 ▲ 1.85% USD/CRC 442.74 ▼ 0.10% USD/GTQ 7.64 ▲ 2.06% USD/HNL 26.91 ▲ 2.15% USD/NIO 36.62 ▲ 1.57% USD/VES 909.35 ▼ 0.13% USD/PAB 1.00 — 0.00% USD/BZD 2.00 — 0.00% USD/JMD 157.69 ▲ 1.39% USD/TTD 6.75 ▲ 1.58% EUR/BRL 6.25 ▲ 0.93% BRENT 96.08 ▲ 0.27% WTI 88.92 ▲ 0.20% IRON ORE 161.91 — — COPPER 6.06 ▼ 1.93% GOLD 3,888 ▲ 0.06% SILVER 48.65 ▼ 2.65% SOY 1,233 ▲ 0.47% CORN 446.00 ▲ 0.79% WHEAT 593.50 ▲ 1.58% COFFEE 274.00 ▼ 2.21% SUGAR 18.40 ▲ 0.99% ORANGE JUICE 136.85 ▼ 2.91% COTTON 79.02 ▲ 0.44% COCOA 5,267 ▲ 3.97% BEEF 224.93 ▲ 2.75% CATTLE 335.65 ▼ 0.01% LITHIUM 58.76 ▼ 3.78% PETR4 45.30 ▲ 1.34% VALE3 63.50 ▼ 0.70% ITUB4 42.27 ▲ 1.42% BBDC4 14.52 ▲ 1.40% ABEV3 15.79 ▲ 0.25% BBAS3 15.10 ▼ 2.45% B3SA3 14.89 ▲ 0.88% WEGE3 51.31 ▼ 0.66% PRIO3 63.30 — 0.00% SUZB3 54.77 ▼ 2.27% RENT3 30.07 ▲ 1.66% AZZA3 15.91 ▼ 5.86% CSAN3 3.10 ▲ 8.77% RAIZ4 20.00 ▼ 6.67% PCAR3 2.56 ▲ 7.11% GMAT3 4.25 ▲ 10.68% PSSA3 46.41 ▲ 1.02% CVCB3 0.83 ▼ 1.19% POSI3 3.15 ▼ 6.53% SLCE3 18.28 ▼ 0.44% NATU3 5.13 ▼ 3.75% BRKM5 3.02 ▼ 1.63% RANI3 8.18 — 0.00% CSNA3 3.72 ▼ 12.06%
since 2009
Saturday, November 14, 2026

No data on efficacy against current Covid variants – but European watchdog wants standard approval for Valneva

By · · 2 min read

RIO DE JANEIRO, BRAZIL – It is the sixth Covid vaccine to be approved in the EU: The European Medicines Agency EMA has recommended approval for Valneva’s vaccine (VLA2001); approval by the EU Commission is considered a mere formality.

It is interesting to note that a lot of data on the vaccine is not available – but instead of conditional approval, they would still like to allow a standard approval directly. This vaccine also uses gene therapy.

Read also: Check out our coverage on curated alternative narratives

Free daily brief — no card needed
Get every Crypto story in one morning email
We build you a personalized brief around the topics you follow — free for 7 days. Love it? Your first month after that is US$1.

The EMA considers a study with not even 3,000 participants to be significant enough to recommend standard approval.

No data on efficacy against current Covid variants - but European watchdog wants standard approval for Valneva.
No data on efficacy against current Covid variants – but European watchdog wants standard approval for Valneva.
RT
Ask Rio Times
17 years of Latin America reporting, on demand.
Open the full Ask Rio Times →

This is not a placebo-controlled trial, as is actually considered the gold standard for efficacy studies, but merely an immunobridging study comparing the immune response to Valneva’s vaccine with that to AstraZeneca’s controversial vector vaccine.

In the study, antibody production was reportedly higher in Valneva vaccinees – but only against the original strain of SARS-CoV-2, which has not been widely used for a long time. Data are lacking on efficacy against omicron. In terms of how many vaccinees responded with high antibody responses after the shot, the two vaccines showed little difference.

The LatAm Brief

One email, every weekday morning. What moved in Latin American markets, politics and expat life.

Yesterday’s subject line: “Trump threatens to double tariffs on Mexico”

The recommendation for approval applies to persons between 18 and 50 years of age; there are also no meaningful data for persons over 50 years of age.

As originally reported for the mRNA and vector vaccines, the only known side effects to date are pain at the injection site, fatigue, headache, muscle pain, and nausea/vomiting.

The Valneva vaccine is an inactivated whole-virus vaccine that relies on two adjuvants at once – alum and CpG 1018, the latter of which is synthetic DNA and therefore gene therapy. It is therefore wrong, according to experts, to call the vaccine a traditional dead vaccine.

This article was produced by The Rio Times’ automated AI newsroom. Editorial responsibility: Matthias Camenzind, Publisher and Editor-in-Chief. The Rio Times also runs Ask Rio Times, which answers from 100,000+ of our own articles, the daily Latin America Power Map, and prediction-market odds on elections and markets.. How we use AI · Report an error

Read More from The Rio Times

Brazil runoff date: Sunday, October 25, poll closing times and when results start · Brazil runoff polls: Flávio 51%, Lula 49% · Kalshi and Polymarket odds

Rotate for Best Experience

This report is optimized for landscape viewing. Rotate your phone for the full experience.